ACHIEVE LIFE SCIENCES, INC. — Director's Dealing 2010

May 18, 2010

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ONCOGENEX PHARMACEUTICALS, INC. (OGXI)
CIK: 0000949858
Period of Report: 2010-05-13

Reporting Person: MARTINO MICHAEL A (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2010-05-13	Common Stock	M	2726	$6.66	Acquired	13726	Direct
2010-05-13	Common Stock	S	2726	$19.1999	Disposed	11000	Direct
2010-05-17	Common Stock	M	10368	$6.66	Acquired	21368	Direct
2010-05-17	Common Stock	S	10368	$18.5297	Disposed	11000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2010-05-13	stock option (right to buy)	$6.66	M	2726	Disposed	2018-03-18	Common Stock (2726)	Direct
2010-05-17	Stock option (right to buy)	$6.66	M	10368	Disposed	2018-03-18	Common (10368)	Direct

Footnotes

F1: This is the weighted average price. The prices ranged from $18.50 to $19.00. The reporting person undertakes to provide on request a detailed breakout of the pricing.